Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03512210 · ClinicalTrials.gov registry record · Phase 4

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

A Phase 4 study of Hepatitis C and HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

Completed
Registry status
Phase 4
Development phase
400
Enrollment target
20
Study locations

NCT03512210 is a Phase 4 study of Hepatitis C and HIV-1-infection that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 400 participants, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03512210, a Phase 4 study of Hepatitis C and HIV-1-infection, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

COMPLETED
Registry status
Phase 4
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

To achieve global hepatitis C virus (HCV) elimination by 2030, 80% of the \~71 million people with chronic HCV infection will need to be treated, necessitating simplification of treatment delivery and associated laboratory monitoring without compromising efficacy or safety. The COVID-19 pandemic has further highlighted the need for innovative models of health care delivery that minimize face-to-face patient-provider contact. The purpose of this study was to evaluate the feasibility, safety, and efficacy of a minimal monitoring (MINMON) strategy to deliver interferon- and RBV-free, pan-genotypic DAA therapy to treat active HCV in HCV treatment naïve participants.

Conditions Studied

Hepatitis C HIV-1-infection Liver Diseases

Interventions

  • DRUG Sofosbuvir/Velpatasvir (SOF/VEL)
  • OTHER Minimal Monitoring (MINMON) Strategy

Study Locations (20)

California

  • University of Southern California (1201) - Los Angeles
  • UCLA CARE Center CRS (601) - Los Angeles
  • Ucsd, Avrc Crs (701) - San Diego
  • Ucsf Aids Crs (801) - San Francisco

New York

  • Weill Cornell Chelsea CRS (7804) - New York
  • Columbia Physicians and Surgeons CRS (30329) - New York
  • Weill Cornell Upton CRS (7803) - New York
  • University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) - Rochester

Illinois

  • Northwestern University CRS (2701) - Chicago
  • Rush Univ. Med. Ctr. ACTG CRS (2702) - Chicago

Massachusetts

  • Massachusetts General Hospital (MGH) CRS (101) - Boston
  • Brigham and Women's Hosp. ACTG CRS (107) - Boston

Alabama

  • Alabama CRS (31788) - Birmingham

Colorado

  • University of Colorado Hospital CRS (6101) - Aurora

District of Columbia

  • Whitman Walker Health CRS (31791) - Washington D.C.

Georgia

  • The Ponce de Leon Center CRS (5802) - Atlanta

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2018-10-22
Est. Completion 2021-02-28
Phase Phase 4

Sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03512210

The ClinicalTrials.gov registry entry for NCT03512210 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (79% lower). The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Sofosbuvir/Velpatasvir (SOF/VEL) is the first listed.

NCT03512210 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Illinois.

Frequently Asked Questions

What is clinical trial NCT03512210 about?

NCT03512210 is a clinical study titled "Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection". To achieve global hepatitis C virus (HCV) elimination by 2030, 80% of the \~71 million people with chronic HCV infection will need to be treated, necessitating simplification of treatment delivery and associated laboratory monitoring without compromising efficacy or safety. The COVID-19 pandemic has...

What is the current status of trial NCT03512210?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2018-10-22. Estimated completion is 2021-02-28.

What conditions does trial NCT03512210 study?

This clinical trial studies the following conditions: Hepatitis C, HIV-1-infection, Liver Diseases.

What interventions are being tested in trial NCT03512210?

The interventions under investigation include: Sofosbuvir/Velpatasvir (SOF/VEL) (DRUG), Minimal Monitoring (MINMON) Strategy (OTHER).

Who is sponsoring clinical trial NCT03512210?

This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03512210 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C

All registered trials for this condition

HIV-1-infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.